open access

Vol 2, No 4 (2006)
Review paper
Published online: 2006-09-26
Get Citation

Bisphosphonates in prevention and control of skeletal-related events in cancer patients with bone metastases

Kazimierz Drosik, Maciej Krzakowski, Jerzy Jarosz, Maria Kraj, Krzysztof Krzemieniecki, Tadeusz Pieńkowski, Beata Utracka-Hutka, Jacek Jassem, Cezary Szczylik, Marek Wojtukiewicz, Marek Ziobro
Onkol. Prak. Klin 2006;2(4):152-164.

open access

Vol 2, No 4 (2006)
REVIEW ARTICLES
Published online: 2006-09-26

Abstract

The current use of bisphosphonates in metastatic bone disease includes their administration to prevent skeletal-related events, reduce bone pain and improve quality of life. The results of several randomized trials have established efficacy of bisphosphonates (clodronate and pamidronate) against bone complications in patients with breast cancer and multiple myeloma. Recently, trials of zoledronic acid have confirmed its value in prostate cancer and some other solid tumours (eg. non-small-cell lug cancer). Ibandronate is a new bisphosphonate of confirmed efficacy in patients with breast cancer and bone metastases. Bisphosphonates have also some effect on metastatic bone pain. The safety profiles of bisphosphonates are important - although bisphosphonates are well tolerated in general, they are sometimes associated with adverse events (eg., hypocalcemia, renal toxicity, and osteonecrosis of the jaw). The evidence from adjuvant clinical trials of bisphosphonates is conflicting and more prospective studies are needed to further investigate this issue. This review relates to the efficacy and safety of bisphosphonates in various clinical situations.

Abstract

The current use of bisphosphonates in metastatic bone disease includes their administration to prevent skeletal-related events, reduce bone pain and improve quality of life. The results of several randomized trials have established efficacy of bisphosphonates (clodronate and pamidronate) against bone complications in patients with breast cancer and multiple myeloma. Recently, trials of zoledronic acid have confirmed its value in prostate cancer and some other solid tumours (eg. non-small-cell lug cancer). Ibandronate is a new bisphosphonate of confirmed efficacy in patients with breast cancer and bone metastases. Bisphosphonates have also some effect on metastatic bone pain. The safety profiles of bisphosphonates are important - although bisphosphonates are well tolerated in general, they are sometimes associated with adverse events (eg., hypocalcemia, renal toxicity, and osteonecrosis of the jaw). The evidence from adjuvant clinical trials of bisphosphonates is conflicting and more prospective studies are needed to further investigate this issue. This review relates to the efficacy and safety of bisphosphonates in various clinical situations.
Get Citation

Keywords

bisphosphonates; bone metastases; skeletal-related events

About this article
Title

Bisphosphonates in prevention and control of skeletal-related events in cancer patients with bone metastases

Journal

Oncology in Clinical Practice

Issue

Vol 2, No 4 (2006)

Article type

Review paper

Pages

152-164

Published online

2006-09-26

Bibliographic record

Onkol. Prak. Klin 2006;2(4):152-164.

Keywords

bisphosphonates
bone metastases
skeletal-related events

Authors

Kazimierz Drosik
Maciej Krzakowski
Jerzy Jarosz
Maria Kraj
Krzysztof Krzemieniecki
Tadeusz Pieńkowski
Beata Utracka-Hutka
Jacek Jassem
Cezary Szczylik
Marek Wojtukiewicz
Marek Ziobro

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl